Myocardial gene delivery of inhibitor-2 improved left ventricular fractional shortening at 1 week and significantly extended survival time for 3 months in a cardiomyopathic hamster model.
Does myocardial gene transfer of inhibitor-2 improve cardiac function and survival in a cardiomyopathic hamster model of heart failure?
Inhibition of protein phosphatase 1 via inhibitor-2 gene delivery improves cardiac function and survival in a genetic cardiomyopathy model, suggesting a potential novel therapeutic target for heart failure.
The type 1 protein phosphatase (PP1) has been reported to be overactivated in the failing heart, leading to a depression in cardiac function. We investigated whether in vivo PP1 inhibition by myocardial gene transfer of inhibitor-2 (INH-2), an endogenous PP1 inhibitor, alleviates heart failure (HF) progression in the cardiomyopathic (CM) hamster, a well-established HF model. Adenoviral INH-2 gene delivery improved % fractional shortening of the left ventricle (LV) accompanied by reduced chamber size at 1 wk. In vivo myocardial INH-2 gene delivery induced an increase in cytosolic PP1 catalytic subunit alpha (PP1Calpha) without inducing the corresponding increase in cytosolic PP1 activity. On the other hand, INH-2 delivery induced a decrease in microsomal PP1Calpha, resulting in a preferential decrease in microsomal PP1 activity, thereby increasing in phospholamban phosphorylation at Ser16. INH-2 gene transfer alleviated brain natriuretic peptide expression, presumably reflecting improved cardiac function. Moreover, adeno-associated virus-mediated INH-2 gene delivery significantly extended the survival time for 3 mo. These results indicate that increased PP1 activity is an exacerbating factor during progression of genetic cardiomyopathy and modulation of PP1 activity by INH-2 provides a potential new treatment for HF without activating protein kinase A signaling in cardiomyocytes.
Yamada et al. (Thu,) conducted a other in Heart failure in genetic cardiomyopathy. Myocardial gene transfer of inhibitor-2 (INH-2) was evaluated on Fractional shortening of the left ventricle and survival time. Myocardial gene delivery of inhibitor-2 improved left ventricular fractional shortening at 1 week and significantly extended survival time for 3 months in a cardiomyopathic hamster model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: